NCT00607607View on ClinicalTrials.gov

A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

January 31, 2012

Conditions
Ovarian CancerEndometrial Cancer
Interventions
DRUG

MKC-1

capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles

Trial Locations (6)

L8V 5C2

Juravinski Cancer Centre, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

N6A 4L6

London Health Sciences Centre, London

L5M 2N1

Credit Valley Hospital, Mississauga

M5G 2M9

Princess Margaret Hospital, Toronto

H2L 4M1

Hopital Notre-Dame du CHUM, Montreal

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY